On the heels of the Pfizergan breakup, one would think Allergan’s price would rise back to its pre-merger-announcement levels — but two factors are holding it back.
On the heels of the Pfizergan breakup, one would think Allergan’s price would rise back to its pre-merger-announcement levels — but two factors are holding it back.